Literature DB >> 1099888

The heart in myasthenia gravis.

T C Gibson.   

Abstract

The cardiac changes associated with myasthenia gravis have been reviewed and specific areas explored. There is no doubt concerning the involvement of the myocardium in this disease as indicated by clinical, ECG, vectorcardiographic, and autopsy data. The doubt lies in the precipitating factor for the pathology found. On the one hand the whole picture could be a direct result of the pathologic process of myasthenia gravis. On the other hand the patient with myasthenia gravis, during the natural history of the disease, encounters many iatrogenic and coincidental variables which could influence the nature of the clinical findings and autopsy data. One fact seems reasonably clear: The association of myocardial pathology with thymoma, especially malignant thymoma, is well established for the more severe form of the myocardial disease. Furthermore, the hypothesis that cardiac muscle antibodies give rise to such reactions is attractive, although not fully resolved. If such cases are excluded then there remain others where cardiac pathology could be due to other disease, primarily coronary heart disease, in the older group. In addition, the mode of death of some patients indicates that intercurrent respiratory problems could play a part. Most patients in this group do not seem to have cardiac abnormalities due to the pathologic process of myasthenia. There is in addition a small group where very striking cardiovascular findings suggestive of myocarditis are found. There is not necessarily a thymoma and no other specific etiologic factors can be found. These are rare cases and might still be related to disorders of immune mechanisms. In conclusion it can be stated that, although there is now a considerable body of evidence concerning the heart in myasthenia gravis, the implication of specific pathology for this neuromuscular disorder affecting the heart must be considered, in the traditional Scottish legal sense, as "not proven."

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1099888     DOI: 10.1016/0002-8703(75)90330-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  The presence of dysautonomia in different subgroups of myasthenia gravis patients.

Authors:  Ana Nikolić; Stojan Perić; Tanja Nišić; Srdjan Popović; Miroljub Ilić; Vidosava Rakočević Stojanović; Dragana Lavrnić
Journal:  J Neurol       Date:  2014-08-14       Impact factor: 4.849

2.  Left ventricular long-axis function in myasthenia gravis.

Authors:  Jone Furlund Owe; Einar Skulstad Davidsen; Geir Egil Eide; Eva Gerdts; Nils Erik Gilhus
Journal:  J Neurol       Date:  2008-12-08       Impact factor: 4.849

3.  Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study.

Authors:  Sudhir Sharma; Vivek Lal; Sudesh Prabhakar; Ritesh Agarwal
Journal:  Ann Indian Acad Neurol       Date:  2013-04       Impact factor: 1.383

4.  Electrocardiography as the First Step for the Further Examination of Cardiac Involvement in Myasthenia Gravis.

Authors:  Takao Kato; Sayako Hirose; Shogo Kumagai; Akihiko Ozaki; Sadayuki Matsumoto; Moriaki Inoko
Journal:  Biomed Res Int       Date:  2016-01-17       Impact factor: 3.411

5.  Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis.

Authors:  Yoko Fukasawa; Kazuya Sasaki; Maika Natsume; Makoto Nakashima; Shuji Ota; Kiyotaka Watanabe; Yoshihisa Takahashi; Fukuo Kondo; Ken Kozuma; Nobuhiko Seki
Journal:  Case Rep Oncol       Date:  2017-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.